NVS Jan 2025 90.000 put
| Previous close | 2.3000 |
| Open | 2.2000 |
| Bid | 2.0500 |
| Ask | 2.3000 |
| Strike | 90.00 |
| Expiry date | 2025-01-17 |
| Day's range | 2.2000 - 2.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 313 |
Insider MonkeyNovartis AG (NYSE:NVS) Q1 2024 Earnings Call Transcript
Novartis AG (NYSE:NVS) Q1 2024 Earnings Call Transcript April 23, 2024 Novartis AG isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and good afternoon, and welcome to the Novartis Q1 2024 Results Release Conference Call and Live Webcast. […]
GlobeNewswireNovartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic differences in babies under 5 kg The CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, dem
